ACP Recommends Hormone Therapy for Menopausal Symptoms

The American College of Physicians (ACP) has issued new guidance recommending hormone therapy as the first-line treatment for women experiencing menopausal vasomotor symptoms, such as hot flashes and night sweats. This updated recommendation marks a significant shift in clinical practice, aiming to provide more effective relief for a common and often disruptive aspect of menopause. The guidance, published in the Annals of Internal Medicine, specifies that women with a uterus should receive a combination of estrogen and progesterone. This dual therapy is crucial to protect the uterine lining from the potential adverse effects of unopposed estrogen, which can lead to endometrial hyperplasia and an increased risk of uterine cancer. For women who have undergone a hysterectomy (surgical removal of the uterus), estrogen therapy alone is recommended.

The ACP's updated stance is based on a comprehensive review of the latest scientific evidence, which indicates that the benefits of hormone therapy for symptom relief generally outweigh the risks for most healthy women in their 50s or within 10 years of menopause onset. The organization emphasizes that the decision to use hormone therapy should be individualized, taking into account a woman's specific symptoms, medical history, and personal preferences. Clinicians are advised to discuss the potential benefits, risks, and alternatives with their patients, prescribing the lowest effective dose for the shortest duration necessary to manage symptoms. This approach aims to maximize symptom relief while minimizing potential long-term health concerns.

Previous guidelines and public perception of hormone therapy were significantly influenced by the Women's Health Initiative (WHI) study, which began in 1991. Early reports from the WHI suggested increased risks of breast cancer, heart disease, stroke, and blood clots associated with hormone therapy. However, subsequent analyses and a deeper understanding of the study's design and patient population have led to a more nuanced view. The ACP's current recommendation reflects this evolving scientific understanding, acknowledging that the risks are not uniform across all women and depend on factors such as age, time since menopause, and the specific type and dosage of hormone therapy used. The new guidance differentiates between estrogen-plus-progestin therapy and estrogen-only therapy, as well as considering the timing of initiation relative to menopause.

The ACP's updated recommendation is expected to influence clinical practice across the United States, potentially leading to increased prescriptions of hormone therapy for menopausal symptom management. The organization also stresses the importance of ongoing research to further refine understanding of hormone therapy's long-term effects and to identify optimal treatment strategies for diverse patient populations. This guidance aims to empower both patients and healthcare providers with evidence-based information to make informed decisions about managing menopausal symptoms effectively and safely.